Premenstrual Syndrome Treatment Market Forecast 2025–2033
According to Renub Research Premenstrual Syndrome (PMS) Treatment Market is anticipated to grow from US$ 1,385.44 million in 2024 to US$ 1,909.67 million by 2033, expanding at a CAGR of 3.63% over 2025–2033. Key factors supporting this growth include rising awareness of women’s health, increasing incidence of PMS and severe PMS-related disorders, advancements in hormonal and non-hormonal therapies, and a global push toward accessible and effective women-centric healthcare solutions.
Premenstrual Syndrome Treatment Market Outlook
Premenstrual Syndrome (PMS) treatment encompasses a wide range of medical, pharmaceutical, and therapeutic interventions designed to address the physical, emotional, and behavioral symptoms experienced during the luteal phase of the menstrual cycle. These symptoms may include mood swings, irritability, abdominal cramps, headaches, bloating, breast tenderness, fatigue, anxiety, and sleep disturbances. Treatment options include hormonal contraceptives, antidepressants such as SSRIs, NSAIDs, diuretics, and lifestyle-based approaches such as diet adjustments, physical activity, stress management, and supplementation.
Globally, PMS treatment adoption is rising as more women seek clinical support and symptom relief. Awareness initiatives, improved gynecologic care accessibility, and destigmatization of women’s reproductive health issues have led to earlier diagnosis and better management. Over-the-counter vitamins, herbal formulations, and supplements have become widely popular due to their convenience and affordability. Meanwhile, ongoing research into hormonal regulation, neurotransmitter balance, and personalized therapy approaches is elevating the standard of care.
Healthcare systems worldwide recognize PMS as a critical factor influencing women’s productivity, emotional well-being, and quality of life. This recognition has expanded treatment availability in hospitals, clinics, and retail pharmacies, positioning PMS management as an essential component of women’s healthcare.
Request a free sample copy of the report:https://www.renub.com/request-sample-page.php?gturl=premenstrual-syndrome-treatment-market-p.php
Drivers of Growth in the Premenstrual Syndrome Treatment Market
Increased Awareness and Education on Women’s Health
Growing emphasis on women’s health education significantly contributes to market expansion. Awareness campaigns from healthcare associations, government bodies, and women-focused organizations help women identify PMS symptoms and understand available treatment options. As stigma declines, more women seek medical evaluation, boosting adoption of both pharmaceutical and non-pharmaceutical therapies.
Statistics from the National Institutes of Health (NIH) suggest that nearly 75% of women experience PMS symptoms, while around 5% endure severe symptoms classified as Premenstrual Dysphoric Disorder (PMDD). The rising visibility of PMDD and access to specialized care increase market demand for targeted treatments.
Pharmaceutical and Non-Pharmaceutical Treatment Advances
Innovations across hormonal and non-hormonal treatment pathways continue to strengthen the PMS treatment landscape. SSRIs and SNRIs, which regulate serotonin levels, show strong efficacy for mood symptoms. Combination oral contraceptives provide relief by stabilizing hormonal fluctuations, while NSAIDs and diuretics help manage pain and bloating.
Growing consumer interest in natural remedies, nutritional supplements, and herbal treatments adds diversity to the therapy ecosystem. Healthcare professionals increasingly adopt personalized treatment plans combining pharmaceuticals with lifestyle and dietary adjustments.
A notable development occurred in September 2023, when Vistagen reported promising results from a Phase 2A study evaluating PH80 for acute PMDD symptom treatment, highlighting innovation in neuroactive nasal spray therapies.
Increasing Healthcare Access and Urbanization
Rising urbanization and improved healthcare infrastructure in developing regions contribute to higher adoption of PMS therapies. Women in urban areas have greater access to specialists, diagnostic facilities, pharmacies, telemedicine platforms, and insurance plans that support treatment affordability.
The spread of digital health services equips more women to consult gynecologists remotely, especially in regions with limited physical healthcare availability. Enhanced access to retail pharmacies and online drug delivery also supports the demand for PMS treatments.
Challenges of the Premenstrual Syndrome Treatment Market
Limited Diagnosis and Awareness in Developing Regions
Despite global progress, PMS remains widely underdiagnosed in rural and economically disadvantaged areas. Limited awareness, cultural stigma, and lack of gynecological services prevent women from seeking medical care for PMS or PMDD. Weak healthcare infrastructure and financial limitations further restrict access to advanced treatments. This diagnosis gap inhibits market growth and delays opportunities to introduce newer therapies in underserved regions.
Side Effects and Compliance Issues with Treatment Options
Pharmaceutical treatments such as SSRIs, hormonal contraceptives, and NSAIDs can cause adverse effects including nausea, weight gain, mood fluctuations, and gastrointestinal discomfort. These side effects may hinder treatment adherence, resulting in poor outcomes and discontinued use. Long-term or inconsistent use of PMS medication also affects therapeutic effectiveness.
While non-pharmaceutical therapies present fewer risks, their benefits may be limited for women with severe symptoms, creating a need for more potent, well-tolerated options. Enhancing drug safety profiles and improving patient compliance remain essential challenges for market participants.
Premenstrual Syndrome Treatment Market by Drug Type
Analgesics Premenstrual Syndrome Treatment Market
Analgesics—particularly NSAIDs like ibuprofen and naproxen—are among the most widely used PMS treatments due to their efficacy in reducing pain, cramps, and headaches. Their affordability and accessibility make them popular for self-managed symptom relief. With increasing product availability in pharmacies, convenience stores, and online platforms, this category continues to experience strong, steady demand.
Prescription Premenstrual Syndrome Treatment Market
This segment includes SSRIs, hormonal contraceptives, and diuretics, which are essential for managing moderate to severe PMS or PMDD. Healthcare providers prescribe these medications for patients experiencing significant emotional and physical disruption. Growing public awareness of PMDD and increasing visits to women’s health clinics contribute to rising adoption of prescription therapies.
Ongoing innovation strengthens the segment. For instance, in March 2024, Pfizer Inc. launched its oral therapy Loryna for PMDD management, marking a milestone in addressing unmet needs among women with severe PMS symptoms.
Premenstrual Syndrome Treatment Market by Distribution Channel
Premenstrual Syndrome Hospital Pharmacies Treatment Market
Hospital pharmacies represent a key distribution channel for prescription PMS drugs, especially for severe cases diagnosed by gynecologists and reproductive health specialists. Hospitals often stock advanced hormonal therapies and psychiatric medications used for PMDD. Growth in hospital-based gynecology services and increasing awareness among clinicians about PMS and PMDD enhance demand in this segment.
Regional Analysis of the Premenstrual Syndrome Treatment Market
United States Premenstrual Syndrome Treatment Market
The U.S. leads the global PMS treatment market due to its robust healthcare infrastructure, high awareness levels, and widespread use of both prescription and over-the-counter medications. Insurance reimbursement programs, women’s health promotion initiatives, and pharmaceutical innovation significantly boost treatment adoption. As PMDD diagnosis increases and personalized treatment strategies gain attention, the U.S. market continues to expand.
France Premenstrual Syndrome Treatment Market
France benefits from comprehensive healthcare access and strong women’s health advocacy. French consumers show increasing acceptance of hormonal therapy and pharmaceutical treatments for PMS relief. Retail and hospital pharmacies play central roles in distribution. Favorable reimbursement systems and growing PMDD recognition contribute to consistent market growth.
China Premenstrual Syndrome Treatment Market
China’s PMS treatment market is expanding rapidly due to urbanization, improved healthcare services, and rising health literacy. OTC analgesics and herbal remedies remain popular, but prescription treatments are gaining traction in metropolitan areas. Government investment in women’s healthcare and increasing use of telemedicine enhance diagnosis and treatment uptake despite persistent underdiagnosis in rural regions.
Brazil Premenstrual Syndrome Treatment Market
Brazil’s market is supported by increased reproductive health awareness and accessible pharmacy networks. Both hormonal therapies and analgesics enjoy strong demand, especially in urban areas. Government initiatives promoting women’s health and rising telemedicine usage are expanding treatment reach into underserved communities.
Saudi Arabia Premenstrual Syndrome Treatment Market
Saudi Arabia is experiencing rising demand for PMS treatments as Vision 2030 reforms advance women’s healthcare access. Hospital pharmacies dominate prescription distribution, while retail and online pharmacies supply OTC pain relievers and supplements. Changing cultural attitudes, urbanization, and growing disposable income collectively support market growth.
Market Segmentation
Drug Type
- Analgesics
- Antidepressants
- Oral Contraceptives and Ovarian Suppression Agents
- Others
Type
- Prescription
- Over-the-Counter
Distribution Channel
- Hospital Pharmacies
- Drug Stores and Retail Pharmacies
- Online Stores
Country Coverage
North America: United States, Canada
Europe: France, Germany, Italy, Spain, United Kingdom, Belgium, Netherlands, Turkey
Asia Pacific: China, Japan, India, South Korea, Thailand, Malaysia, Indonesia, Australia, New Zealand
Latin America: Brazil, Mexico, Argentina
Middle East & Africa: Saudi Arabia, UAE, South Africa
Key Companies Covered
Each company includes: Overview, Key Person, Recent Developments, SWOT Analysis, Revenue Analysis
- AbbVie Inc.
- BASF SE
- Bayer AG
- Reddy’s Laboratories Ltd
- Eli Lilly and Company
- GlaxoSmithKline Plc.
- Lundbeck A/S
- Pfizer Inc.
- SHIONOGI & Co. Ltd.
